Evotec SE (EVO) Income from Continuing Operations (2009 - 2025)
Evotec SE (EVO) posted Income from Continuing Operations of 120365220.22 for Q4 2025, down 240274.03% sequentially from 50074.14 in Q3 2025, and up 42.5% YoY from 84469503.11 in Q4 2024.
Evotec SE (EVO) Income from Continuing Operations (2009 - 2025) Analysis & Trends
Evotec SE has reported Income from Continuing Operations for 9 years, with the latest figure at 120365220.22 in Q4 2025.
- Quarterly Income from Continuing Operations rose 42.5% year-over-year to 120365220.22 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 329789072.46 (down 10.08% YoY) and the FY2025 annual result came in at 120498292.51, up 42.49% from the prior year.
- Income from Continuing Operations declined to 120365220.22 in Q4 2025 per EVO's latest filing, from 50074.14 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 246254899.13 in Q4 2021 and troughed at 209314347.96 in Q4 2024.
- A 5-year average of 23523562.29 and a median of 22125.42 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2024: Income from Continuing Operations surged 8771.52% in 2021, then slumped 361.5% in 2024.
- Over 5 years, Income from Continuing Operations stood at 246254899.13 in 2021, then plunged by 172.83% to 179338481.97 in 2022, then surged by 49.68% to 90236548.48 in 2023, then plunged by 131.96% to 209314347.96 in 2024, then surged by 42.5% to 120365220.22 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 120365220.22, 50074.14, and 209314347.96 for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Evotec SE | 681.90 Mn | 681.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.37 Mn |
| Sep 30, 2025 | -50,074.14 |
| Dec 31, 2024 | -209.31 Mn |
| Sep 30, 2024 | -59,430.15 |
| Dec 31, 2023 | -90.24 Mn |
| Sep 30, 2023 | 22,726.50 |
| Jun 30, 2023 | -13,888.14 |
| Dec 31, 2022 | -179.34 Mn |
| Sep 30, 2022 | 39,779.45 |
| Jun 30, 2022 | -22,125.42 |
| Mar 31, 2022 | -72,868.90 |
| Dec 31, 2021 | 246.25 Mn |
| Sep 30, 2021 | 160,102.41 |
| Jun 30, 2021 | 73,489.46 |
| Mar 31, 2021 | 68,554.02 |
| Dec 31, 2020 | 7.47 Mn |
| Sep 30, 2020 | 1,804.68 |
| Dec 31, 2019 | 41.30 Mn |
| Sep 30, 2010 | 1,282.23 |
| Jun 30, 2010 | 2,369.92 |